Pharmaceutical uses of staurosporine derivatives

• US 8,575,146 B2
• Filed: 06/17/2004
• Issued: 11/05/2013
• Est. Priority Date: 06/18/2003
• Status: Active Grant

• Current Assignee: Novartis Pharmaceuticals Corporation (Novartis Ag)
• Original Assignee: Novartis Ag
• Inventors: Coutre, Steven
• Primary Examiner(s): JEAN-LOUIS, SAMIRA JM
• Application Number:
  US10/560,669
• Publication Number:
  US 20070299049A1
• Time in Patent Office: 3,428 Days
• Field of Search: 514/211.08, 540/545
• US Class Current: 514/211.08
• CPC Class Codes: A61K 31/553 having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/14 Decongestants or antiallergics
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics
• CPC Class Codes: C07D 498/16 Peri-condensed systems

Abstract

This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.

Claims

1. A method of treating mastocytosis, which comprises administering a therapeutically effective amount of a compound of formula (VII)

2. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles.

3. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

4. A method according to claim 1, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

5. A method according to claim 1, wherein the compound of formula VII is administered three times a day, for a total dose of 225 mg daily.

6. A method according to claim 1, wherein the compound of formula VII is administered orally.

7. A method according to claim 1, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

8. A method according to claim 1, wherein up to 125 mg per day of the compound of formula VII is administered.

9. A method according to claim 4, wherein the compound of formula VII is administered orally.

10. A method according to claim 9, wherein the compound of formula VII is administered as a microemulsion.

11. A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of a compound of formula (VII)

12. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles.

13. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

14. A method according to claim 11, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

15. A method according to claim 11, wherein the compound of formula VII is administered orally.

16. A method according to claim 11, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

17. A method according to claim 11, wherein up to 125 mg per day of the compound of formula VII is administered.

18. A method according to claim 14, wherein the compound of formula VII is administered orally.

19. A method according to claim 18, wherein the compound of formula VII is administered as a microemulsion.